The company, based at Stevenage Bioscience Catalyst, UK, raised £11.5m in Series A financing to advance the molecules into clinical studies.
Funding will primarily be focused on the advanced neurokinin-1 receptor antagonist that is being moved for another indication, according to NeRRe.
NeRRe chief executive officer Dr Emiliangelo Ratti said, "With our knowledge and insights into the neurokinin receptor system, we look forward to developing these assets in high value indications where there is unmet need."